Australia’s Therapeutic Goods Administration (TGA) has approved Wegovy (semaglutide) in tablet form for eligible adults. The new formulation gives some people an alternative to the injection for long-term weight management. The Australian regulator made its decision on 2 November 2026, registered the tablets on 3 November and published the decision summary on 11 November.
Registration does not tell you when a pharmacy will have stock, what the tablets will cost or whether they will be subsidised. It is also not an instruction to switch from another form of semaglutide.
Who does the Australian approval cover?
For weight management, the tablets are approved alongside a reduced-energy diet and increased physical activity for adults with a body mass index (BMI) of 30 or more, or a BMI of at least 27 and below 30 with at least one weight-related health condition. The tablet approval is for adults. The product information lists a separate adolescent indication for the injection, not the tablet.
There is also a narrower cardiovascular indication. The tablets can be used alongside standard care to reduce the risk of serious cardiovascular events in adults with established cardiovascular disease, a BMI of at least 27 and without established type 1 or type 2 diabetes. Those restrictions apply to the cardiovascular indication; they are not the same as the eligibility criteria for weight management.
What did the main tablet trial find?
OASIS 4 was a randomised, double-blind trial involving 307 adults with obesity, or overweight with a related health condition, who did not have diabetes. Participants received either oral semaglutide or placebo, with lifestyle support in both groups. At 64 weeks, estimated average weight loss was 13.6% of starting weight with the tablet and 2.2% with placebo. The estimated difference was 11.4 percentage points (95% confidence interval 9.0 to 13.9 percentage points). Those are averages, not predictions for individual patients.
Digestive side effects were reported by 74.0% of participants on semaglutide and 42.2% on placebo. The trial was funded by Novo Nordisk. It did not compare the tablet directly with the injection, and it did not test whether the tablet prevented heart attacks or strokes. It also does not tell us how much weight a person with type 2 diabetes should expect to lose.
Why is there a heart indication if the tablet trial measured weight?
The regulator considered evidence from other semaglutide trials, including SELECT, which tested injectable semaglutide, and assessed how the oral formulation compares in terms of how much medicine reaches the bloodstream. That is different from having a trial that directly measured cardiovascular outcomes with this Wegovy tablet in the population named in the Australian indication.
If you read about heart benefits in the SOUL trial, that is a separate study of a different oral semaglutide regimen in people with type 2 diabetes at high cardiovascular risk. Its results do not make the Australian Wegovy cardiovascular indication apply to people with diabetes.
What should you ask your pharmacist or prescriber?
A tablet can suit someone who would rather avoid injections, but it has specific instructions for taking it. Ask your pharmacist how those instructions fit around breakfast and other medicines. Wegovy, Rybelsus and Ozempic contain semaglutide, but their formulations and approved uses differ. Do not swap or combine them on your own.
Ask what side effects to watch for, especially if you take insulin or another medicine that can cause low blood glucose. Tell your healthcare team about your other medicines and health conditions. For more on potential eye symptoms and when to seek urgent help, see our guide to GLP-1 medicines and sudden vision changes.
Does this mean I can get Wegovy tablets now?
The TGA register confirms that the tablets are registered in Australia. Stock, price and any subsidy are separate questions. A pharmacist can check local availability. This is an Australian decision, so it does not change prescribing rules in other countries.